Roland Klingenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roland Klingenberg has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- David Nanchen
Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland
5 shared publications - Nicolas Rodondi
Institute of Primary Health Care (BIHAM), University of Bern , Mittelstrasse 43, Bern 3012
5 shared publications Arnold von Eckardstein
Institute of Clinical Chemistry, University Hospital Zurich and University of Zurich, Zurich, Switzerland
4 shared publications- Arnold von Eckardstein
Institute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland
4 shared publications Christian M. Matter
Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland; Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland
4 shared publications- Christian M. Matter
Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich, University of Zurich, Zurich, Switzerland
4 shared publications
Latest Publications
- Open Access
- 12 April 2026
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 64, 101918
Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction
- 12 April 2026
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 64, 101918
Open AccessMulti-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction
- Open Access
- 30 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (31) , 4259-4273
Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease
Background and Aims: The gut microbiota is a modulator of cardiometabolic disease. Circulating imidazole propionate (ImP) is a microbiota-derived proatherogenic amino acid metabolite modulating the inflammatory response of myeloid cells, endothelial function and glucose metabolism. This study examined the prognostic value of ImP in patients with coronary artery disease (CAD). Methods: Circulating ImP levels were measured in independent prospective cohorts of patients with acute coronary syndrome (ACS, Switzerland n=4937, Germany n=1497) and chronic coronary syndrome (CCS, Germany n=701). Major adverse cardiovascular events (MACE), defined as the first occurrence of a composite of death, nonfatal myocardial infarction, or nonfatal stroke after admission, were the primary endpoint. Cox models, accounting for established risk factors including the gut-derived cardiovascular risk factor trimethylamine N-oxide (TMAO), were used to evaluate the predictive value of ImP. Results: Circulating ImP was associated with more advanced CAD and with cardiometabolic characteristics including diabetes and elevated high-sensitivity C-reactive protein. High ImP was an independent predictor of MACE (Swiss ACS cohort: hazard ratio [HR] per log2 increase 1.22, 95% confidence interval [CI] 1.10–1.35, P<0.001; German ACS cohort: HR 2.34, 95% CI 1.46–3.76, P<0.001; German CCS cohort: HR 1.32, 95% CI 1.13–1.53, P<0.001) and of mortality (Swiss ACS cohort: HR 1.34, 95% CI 1.17–1.54, P<0.001; German ACS cohort: HR 2.38, 95% CI 1.48–3.82, P<0.001; German CCS cohort: HR 1.50, 95% CI 1.14–1.98, P=0.004) after adjustment for established risk factors. ImP provided predictive value beyond TMAO (Swiss ACS cohort: HR 1.30, 95% CI 1.05–1.61, P=0.014; German CCS cohort: HR 1.31, 95% CI 1.11–1.53, P=0.001). Conclusions: Gut microbiota-derived ImP predicted MACE in patients with CAD independently of traditional risk factors and holds promise as a therapeutic target. ImP may refine risk stratification for personalised secondary prevention strategies.
- 30 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (31) , 4259-4273
Open AccessGut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease
Background and Aims: The gut microbiota is a modulator of cardiometabolic disease. Circulating imidazole propionate (ImP) is a microbiota-derived proatherogenic amino acid metabolite modulating the inflammatory response of myeloid cells, endothelial function and glucose metabolism. This study examined the prognostic value of ImP in patients with coronary artery disease (CAD). Methods: Circulating ImP levels were measured in independent prospective cohorts of patients with acute coronary syndrome (ACS, Switzerland n=4937, Germany n=1497) and chronic coronary syndrome (CCS, Germany n=701). Major adverse cardiovascular events (MACE), defined as the first occurrence of a composite of death, nonfatal myocardial infarction, or nonfatal stroke after admission, were the primary endpoint. Cox models, accounting for established risk factors including the gut-derived cardiovascular risk factor trimethylamine N-oxide (TMAO), were used to evaluate the predictive value of ImP. Results: Circulating ImP was associated with more advanced CAD and with cardiometabolic characteristics including diabetes and elevated high-sensitivity C-reactive protein. High ImP was an independent predictor of MACE (Swiss ACS cohort: hazard ratio [HR] per log2 increase 1.22, 95% confidence interval [CI] 1.10–1.35, P<0.001; German ACS cohort: HR 2.34, 95% CI 1.46–3.76, P<0.001; German CCS cohort: HR 1.32, 95% CI 1.13–1.53, P<0.001) and of mortality (Swiss ACS cohort: HR 1.34, 95% CI 1.17–1.54, P<0.001; German ACS cohort: HR 2.38, 95% CI 1.48–3.82, P<0.001; German CCS cohort: HR 1.50, 95% CI 1.14–1.98, P=0.004) after adjustment for established risk factors. ImP provided predictive value beyond TMAO (Swiss ACS cohort: HR 1.30, 95% CI 1.05–1.61, P=0.014; German CCS cohort: HR 1.31, 95% CI 1.11–1.53, P=0.001). Conclusions: Gut microbiota-derived ImP predicted MACE in patients with CAD independently of traditional risk factors and holds promise as a therapeutic target. ImP may refine risk stratification for personalised secondary prevention strategies.
- Open Access
- 3 June 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (9) , 1345-1358
Ceramides in cardiovascular disease: emerging role as independent risk predictors and novel therapeutic targets
Ceramides are bioactive lipid mediators involved in apoptosis, inflammation, and fibrosis. This narrative review provides a concise overview of the emerging role of ceramides in cardiovascular disease with an emphasis on atherosclerotic vascular disease and heart failure, suggesting the potential use of ceramides in risk stratification and as putative therapeutic targets. Recent developments based on observational evidence and genetic associations, including Mendelian randomization studies in humans, are summarized and put into context with experimental evidence for the role of ceramides in human and animal models of disease. Emerging scores composed of ceramides and phosphatidylcholines that are based on the length and desaturation of the N-acyl chains are discussed in the light of novel data demonstrating age- and sex-specific differences. Also reviewed is the structural heterogeneity of the sphingoid bases, including non-conventional sphingolipids that are increasingly recognized for their importance in health and disease. Lastly, novel targets and potential modalities for tissue-specific transfer of drugs are discussed.
- 3 June 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (9) , 1345-1358
Open AccessCeramides in cardiovascular disease: emerging role as independent risk predictors and novel therapeutic targets
Ceramides are bioactive lipid mediators involved in apoptosis, inflammation, and fibrosis. This narrative review provides a concise overview of the emerging role of ceramides in cardiovascular disease with an emphasis on atherosclerotic vascular disease and heart failure, suggesting the potential use of ceramides in risk stratification and as putative therapeutic targets. Recent developments based on observational evidence and genetic associations, including Mendelian randomization studies in humans, are summarized and put into context with experimental evidence for the role of ceramides in human and animal models of disease. Emerging scores composed of ceramides and phosphatidylcholines that are based on the length and desaturation of the N-acyl chains are discussed in the light of novel data demonstrating age- and sex-specific differences. Also reviewed is the structural heterogeneity of the sphingoid bases, including non-conventional sphingolipids that are increasingly recognized for their importance in health and disease. Lastly, novel targets and potential modalities for tissue-specific transfer of drugs are discussed.
- Open Access
- 18 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (4) , e036033
Microcirculatory Resistance After Primary Percutaneous Coronary Intervention Predicts Residual Myocardial Damage and Scar Formation
Background: Coronary microvascular dysfunction has been associated with adverse cardiovascular events following acute myocardial infarction. This study evaluates the role of the angiography‐derived index of microcirculatory resistance (angio‐IMR) in predicting myocardial damage in patients with ST‐segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). Methods and Results: In this post hoc analysis of the CLEVER‐ACS (Controlled‐Level Everolimus in Acute Coronary Syndromes) trial, the associations between post‐PCI angio‐IMR of infarct‐related coronary arteries (IRAs) and infarct size, microvascular obstruction, and left ventricular ejection fraction at 30 days as assessed by cardiac magnetic resonance were investigated. High post‐PCI angio‐IMR was defined as ≥40 mm Hg*s . In non‐IRAs, angio‐IMR was measured before IRA‐PCI. A total of 52 IRAs and 94 non‐IRAs of 52 patients were analyzed. Post‐PCI angio‐IMR was 41.5 (interquartile range [IQR], 28.5–55.7) mm Hg*s in IRAs and pre‐PCI angio‐IMR was 43.7 (IQR, 31.7–54.0) mm Hg*s in non‐IRAs ( P =0.70). Patients with high post‐PCI angio‐IMR (52%) exhibited a larger myocardial infarct size (36.0 [IQR, 23.0–52.5] g versus 14.5 [IQR, 6.50–26.5] g, P P =0.002) at 30 days as compared with those with low post‐PCI angio‐IMR values. Post‐PCI angio‐IMR positively correlated with myocardial infarct size (r=0.45, P =0.001) and extent of microvascular obstruction (r=0.40, P =0.004) at 30 days. Post‐PCI angio‐IMR predicted myocardial infarct size (area under the curve, 0.78 [IQR, 0.65–0.92]; P =0.001) and extent of microvascular obstruction (area under the curve, 0.74 [IQR, 0.60–0.89]; P =0.009) at 30 days. Conclusions: In patients with ST‐segment–elevation myocardial infarction, post‐PCI angio‐IMR was identified as independent predictor of myocardial infarct size and extent of microvascular obstruction. Registration: URL: https:// clinicaltrials.gov ; Unique Identifier: NCT01529554.
- 18 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (4) , e036033
Open AccessMicrocirculatory Resistance After Primary Percutaneous Coronary Intervention Predicts Residual Myocardial Damage and Scar Formation
Background: Coronary microvascular dysfunction has been associated with adverse cardiovascular events following acute myocardial infarction. This study evaluates the role of the angiography‐derived index of microcirculatory resistance (angio‐IMR) in predicting myocardial damage in patients with ST‐segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). Methods and Results: In this post hoc analysis of the CLEVER‐ACS (Controlled‐Level Everolimus in Acute Coronary Syndromes) trial, the associations between post‐PCI angio‐IMR of infarct‐related coronary arteries (IRAs) and infarct size, microvascular obstruction, and left ventricular ejection fraction at 30 days as assessed by cardiac magnetic resonance were investigated. High post‐PCI angio‐IMR was defined as ≥40 mm Hg*s . In non‐IRAs, angio‐IMR was measured before IRA‐PCI. A total of 52 IRAs and 94 non‐IRAs of 52 patients were analyzed. Post‐PCI angio‐IMR was 41.5 (interquartile range [IQR], 28.5–55.7) mm Hg*s in IRAs and pre‐PCI angio‐IMR was 43.7 (IQR, 31.7–54.0) mm Hg*s in non‐IRAs ( P =0.70). Patients with high post‐PCI angio‐IMR (52%) exhibited a larger myocardial infarct size (36.0 [IQR, 23.0–52.5] g versus 14.5 [IQR, 6.50–26.5] g, P P =0.002) at 30 days as compared with those with low post‐PCI angio‐IMR values. Post‐PCI angio‐IMR positively correlated with myocardial infarct size (r=0.45, P =0.001) and extent of microvascular obstruction (r=0.40, P =0.004) at 30 days. Post‐PCI angio‐IMR predicted myocardial infarct size (area under the curve, 0.78 [IQR, 0.65–0.92]; P =0.001) and extent of microvascular obstruction (area under the curve, 0.74 [IQR, 0.60–0.89]; P =0.009) at 30 days. Conclusions: In patients with ST‐segment–elevation myocardial infarction, post‐PCI angio‐IMR was identified as independent predictor of myocardial infarct size and extent of microvascular obstruction. Registration: URL: https:// clinicaltrials.gov ; Unique Identifier: NCT01529554.
- Open Access
- 15 August 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1448664
Mini-Review: Immunogenic epitopes in apolipoprotein B-100 for atheroprotective immunization
Here, we provide a concise overview of recent developments in the identification of immunogenic epitopes in human apolipoprotein B-100 for immunization against atherosclerotic cardiovascular disease. Major steps forward toward a clinical application of vaccines include the design of humanized mouse models, tetramer-based identification of antigen-specific T cells, and novel analysis tools, such as single-cell RNA sequencing and cytometry by time of flight, to assess temporal and spatial changes in immune cells in atherosclerotic cardiovascular disease.
- 15 August 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1448664
Open AccessMini-Review: Immunogenic epitopes in apolipoprotein B-100 for atheroprotective immunization
Here, we provide a concise overview of recent developments in the identification of immunogenic epitopes in human apolipoprotein B-100 for immunization against atherosclerotic cardiovascular disease. Major steps forward toward a clinical application of vaccines include the design of humanized mouse models, tetramer-based identification of antigen-specific T cells, and novel analysis tools, such as single-cell RNA sequencing and cytometry by time of flight, to assess temporal and spatial changes in immune cells in atherosclerotic cardiovascular disease.
- Open Access
- 23 November 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (7) , 845-855
Drinking patterns of alcohol and risk of major adverse cardiovascular events after an acute coronary syndrome
Aims: To evaluate the risk of alcohol consumption after acute coronary syndromes (ACS). Methods and results: A total of 6557 patients hospitalized for ACS at four Swiss centres were followed over 12 months. Weekly alcohol consumption was collected at baseline and 12 months. Binge drinking was defined as consumption of ≥6 units of alcohol on one occasion. Major adverse cardiovascular events (MACE) were defined as a composite of cardiac death, myocardial infarction, stroke, or clinically indicated target vessel coronary revascularization. Cox regression analysis was performed to assess the risk of MACE in patients with heavy (>14 standard units/week), moderate (7–14 standard units per week), light consumption (<1 standard unit/week), or abstinence, and with binge drinking episodes, adjusted for baseline differences. At baseline, 817 (13.4%) patients reported heavy weekly alcohol consumption. At 1-year follow-up, 695/1667 (41.6%) patients reported having at least one or more episodes of binge drinking per month. The risk for MACE was not significantly higher in those with heavy weekly consumption compared to abstinence [8.6% vs. 10.2%, hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.69–1.36] or light consumption (8.6% vs. 8.5%, HR 1.41, 95% CI 0.97–2.06). Compared to patients with no binge drinking, the risk of MACE was dose-dependently higher in those with binge drinking with less than one episode per month (9.2% vs. 7.8%, HR 1.61, 95% CI 1.23–2.11) or one or more episodes per month (13.6% vs. 7.8%, HR 2.17, 95% CI 1.66–2.83). Conclusion: Binge drinking during the year following an ACS, even less than once per month, is associated with worse clinical outcomes.
- 23 November 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (7) , 845-855
Open AccessDrinking patterns of alcohol and risk of major adverse cardiovascular events after an acute coronary syndrome
Aims: To evaluate the risk of alcohol consumption after acute coronary syndromes (ACS). Methods and results: A total of 6557 patients hospitalized for ACS at four Swiss centres were followed over 12 months. Weekly alcohol consumption was collected at baseline and 12 months. Binge drinking was defined as consumption of ≥6 units of alcohol on one occasion. Major adverse cardiovascular events (MACE) were defined as a composite of cardiac death, myocardial infarction, stroke, or clinically indicated target vessel coronary revascularization. Cox regression analysis was performed to assess the risk of MACE in patients with heavy (>14 standard units/week), moderate (7–14 standard units per week), light consumption (<1 standard unit/week), or abstinence, and with binge drinking episodes, adjusted for baseline differences. At baseline, 817 (13.4%) patients reported heavy weekly alcohol consumption. At 1-year follow-up, 695/1667 (41.6%) patients reported having at least one or more episodes of binge drinking per month. The risk for MACE was not significantly higher in those with heavy weekly consumption compared to abstinence [8.6% vs. 10.2%, hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.69–1.36] or light consumption (8.6% vs. 8.5%, HR 1.41, 95% CI 0.97–2.06). Compared to patients with no binge drinking, the risk of MACE was dose-dependently higher in those with binge drinking with less than one episode per month (9.2% vs. 7.8%, HR 1.61, 95% CI 1.23–2.11) or one or more episodes per month (13.6% vs. 7.8%, HR 2.17, 95% CI 1.66–2.83). Conclusion: Binge drinking during the year following an ACS, even less than once per month, is associated with worse clinical outcomes.
- Open Access
- 23 September 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 30 (17) , 1922-1923
Association of cumulative remnant cholesterol with incident adverse cardiovascular events in the elderly: another piece in the puzzle
Roland Klingenberg, MD; Association of cumulative remnant cholesterol with incident adverse cardiovascular events in the elderly – another piece in the puzzle,
- 23 September 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 30 (17) , 1922-1923
Open AccessAssociation of cumulative remnant cholesterol with incident adverse cardiovascular events in the elderly: another piece in the puzzle
Roland Klingenberg, MD; Association of cumulative remnant cholesterol with incident adverse cardiovascular events in the elderly – another piece in the puzzle,
- Open Access
- 21 October 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (1) , 432-441
Use of Serial Changes in Biomarkers vs. Baseline Levels to Predict Left Ventricular Remodelling After STEMI
Aims: Cellular communication network factor 1 (CCN1) is an independent predictor of MACE after ACS and elevated levels correlated with infarct size after STEMI. We compared the prognostic accuracy of baseline levels of CCN1, NT-proBNP, hsTnT, and ST2 and changes in levels over time to predict the development of structural and functional alterations typical of LV remodelling. Methods: Serial 3-T cMRI scans were performed to determine LVEF, LVEDV, LVESV, infarct size, and relative infarct size, which were correlated with serial measurements of the four biomarkers. The prognostic significance of these biomarkers was assessed by multiple logistic regression analysis by examining their performance in predicting dichotomized cardiac MRI values 12 months after STEMI based on their median. For each biomarker three models were created using baseline (BL), the Δ value (BL to 6 months), and the two values together as predictors. All models were adjusted for age and renal function. Receiver operator curves were plotted with area under the curve (AUC) to discriminate the prognostic accuracy of individual biomarkers for MRI-based structural or functional changes. Results: A total of 44 predominantly male patients (88.6%) from the ETiCS (Etiology, Titre-Course, and Survival) study were identified at a mean age of 55.5 ± 11.5 (SD) years treated by successful percutaneous coronary intervention (97.7%) at a rate of 95.5% stent implantation within a median pain-to-balloon time of 260 min (IQR 124–591). Biomarkers hsTnT and ST2 were identified as strong predictors (AUC > 0.7) of LVEDV and LVEF. BL measurement to predict LVEF [hsTnT: AUC 0.870 (95% CI: 0.756–0.983), ST2: AUC 0.763 (95% CI: 0.615–0.911)] and the Δ value BL-6M [hsTnT: AUC 0.870 (95% CI: 0.756–0.983), ST2: AUC 0.809 (95% CI: 0.679–0.939)] showed a high prognostic value without a significant difference for the comparison of the BL model vs. the Δ-value model (BL-6M) for hsTnT (P = 1) and ST2 (P = 0.304). The combined model that included baseline and Δ value as predictors was not able to improve the ability to predict LVEF [hsTnT: AUC 0.891 (0.791–0.992), P = 0.444; ST2: AUC 0.778 (0.638–0.918), P = 0.799]. Baseline levels of CCN1 were closely associated with LVEDV at 12 months [AUC 0.708 (95% CI: 0.551–0.865)] and infarct size [AUC 0.703 (95% CI: 0.534–0.872)]. Conclusions: Baseline biomarker levels of hsTnT and ST2 were the strongest predictors of LVEF and LVEDV at 12 months after STEMI. The association of CCN1 with LVEDV and infarct size warrants further study into the underlying pathophysiology of this novel biomarker.
- 21 October 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (1) , 432-441
Open AccessUse of Serial Changes in Biomarkers vs. Baseline Levels to Predict Left Ventricular Remodelling After STEMI
Aims: Cellular communication network factor 1 (CCN1) is an independent predictor of MACE after ACS and elevated levels correlated with infarct size after STEMI. We compared the prognostic accuracy of baseline levels of CCN1, NT-proBNP, hsTnT, and ST2 and changes in levels over time to predict the development of structural and functional alterations typical of LV remodelling. Methods: Serial 3-T cMRI scans were performed to determine LVEF, LVEDV, LVESV, infarct size, and relative infarct size, which were correlated with serial measurements of the four biomarkers. The prognostic significance of these biomarkers was assessed by multiple logistic regression analysis by examining their performance in predicting dichotomized cardiac MRI values 12 months after STEMI based on their median. For each biomarker three models were created using baseline (BL), the Δ value (BL to 6 months), and the two values together as predictors. All models were adjusted for age and renal function. Receiver operator curves were plotted with area under the curve (AUC) to discriminate the prognostic accuracy of individual biomarkers for MRI-based structural or functional changes. Results: A total of 44 predominantly male patients (88.6%) from the ETiCS (Etiology, Titre-Course, and Survival) study were identified at a mean age of 55.5 ± 11.5 (SD) years treated by successful percutaneous coronary intervention (97.7%) at a rate of 95.5% stent implantation within a median pain-to-balloon time of 260 min (IQR 124–591). Biomarkers hsTnT and ST2 were identified as strong predictors (AUC > 0.7) of LVEDV and LVEF. BL measurement to predict LVEF [hsTnT: AUC 0.870 (95% CI: 0.756–0.983), ST2: AUC 0.763 (95% CI: 0.615–0.911)] and the Δ value BL-6M [hsTnT: AUC 0.870 (95% CI: 0.756–0.983), ST2: AUC 0.809 (95% CI: 0.679–0.939)] showed a high prognostic value without a significant difference for the comparison of the BL model vs. the Δ-value model (BL-6M) for hsTnT (P = 1) and ST2 (P = 0.304). The combined model that included baseline and Δ value as predictors was not able to improve the ability to predict LVEF [hsTnT: AUC 0.891 (0.791–0.992), P = 0.444; ST2: AUC 0.778 (0.638–0.918), P = 0.799]. Baseline levels of CCN1 were closely associated with LVEDV at 12 months [AUC 0.708 (95% CI: 0.551–0.865)] and infarct size [AUC 0.703 (95% CI: 0.534–0.872)]. Conclusions: Baseline biomarker levels of hsTnT and ST2 were the strongest predictors of LVEF and LVEDV at 12 months after STEMI. The association of CCN1 with LVEDV and infarct size warrants further study into the underlying pathophysiology of this novel biomarker.
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Heavy weekly alcohol consumption versus binge drinking after an acute coronary syndrome and risk of major adverse cardiovascular events at one year follow up
Background: The association between heavy weekly alcohol consumption or binge drinking and the risk of major adverse cardiovascular events (MACE) after acute coronary syndromes (ACS) is still unclear. Purpose: To determine the risks of MACE at one year follow up according to baseline alcohol consumption, especially in patients with heavy weekly alcohol consumption or binge drinking. Methods: We analyzed data of 6053 patients hospitalized in 4 Swiss centres for an ACS and followed over 12 months. Data on alcohol consumption were collected at baseline and at one year follow up after ACS. Binge drinking was defined as the consumption of ≥6 units of alcohol on one occasion, for the 12-months period preceding the one-year follow up. We defined MACE as a composite of cardiac death, myocardial infarction, stroke or clinically indicated target vessel coronary revascularization. We applied Cox regression to assess the risk of MACE associated with heavy alcohol weekly consumption (>14 standard units/week) compared to light consumption (<1 standard unit/week) or abstinence, as well as the risk with binge drinking, compared to no binge drinking, adjusting for baseline differences (age, sex, body-mass index, smoking, diabetes, peripheral artery disease, stroke, hypertension, use of aspirin, anticoagulation, statin, beta-blocker, ACE-inhibitor or ATII receptor blocker). Results: At baseline, 817 (13.4%) patients reported heavy weekly alcohol consumption and 717 (11.8%) reported to have at least one episode of binge drinking per month. The risk for MACE at one year follow up was not increased in those with heavy weekly consumption compared to light consumption (8.7% vs. 8.5%, HR 0.96, 95% CI 0.69–1.33, P=0.80) or no consumption (8.7% vs. 10.3%, HR 1.26, 95% CI 0.88–1.80, P=0.21). However, the risk of MACE was higher in those reporting binge drinking with less than one episode a month (9.4% vs. 7.7%, HR 1.67, 95% CI 1.32–2.12, P<0.001), as well as in those with at least one episode of binge drinking per month (13.4% vs. 7.7%, HR 2.07, 95% CI 1.62–2.65, P<0.001), when compared to no binge drinking. Conclusion: In contrast to regular heavy alcohol consumption, binge drinking behavior is associated with significant increased risk of MACE 12 months after ACS. Funding Acknowledgement: Type of funding sources: None.
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessHeavy weekly alcohol consumption versus binge drinking after an acute coronary syndrome and risk of major adverse cardiovascular events at one year follow up
Background: The association between heavy weekly alcohol consumption or binge drinking and the risk of major adverse cardiovascular events (MACE) after acute coronary syndromes (ACS) is still unclear. Purpose: To determine the risks of MACE at one year follow up according to baseline alcohol consumption, especially in patients with heavy weekly alcohol consumption or binge drinking. Methods: We analyzed data of 6053 patients hospitalized in 4 Swiss centres for an ACS and followed over 12 months. Data on alcohol consumption were collected at baseline and at one year follow up after ACS. Binge drinking was defined as the consumption of ≥6 units of alcohol on one occasion, for the 12-months period preceding the one-year follow up. We defined MACE as a composite of cardiac death, myocardial infarction, stroke or clinically indicated target vessel coronary revascularization. We applied Cox regression to assess the risk of MACE associated with heavy alcohol weekly consumption (>14 standard units/week) compared to light consumption (<1 standard unit/week) or abstinence, as well as the risk with binge drinking, compared to no binge drinking, adjusting for baseline differences (age, sex, body-mass index, smoking, diabetes, peripheral artery disease, stroke, hypertension, use of aspirin, anticoagulation, statin, beta-blocker, ACE-inhibitor or ATII receptor blocker). Results: At baseline, 817 (13.4%) patients reported heavy weekly alcohol consumption and 717 (11.8%) reported to have at least one episode of binge drinking per month. The risk for MACE at one year follow up was not increased in those with heavy weekly consumption compared to light consumption (8.7% vs. 8.5%, HR 0.96, 95% CI 0.69–1.33, P=0.80) or no consumption (8.7% vs. 10.3%, HR 1.26, 95% CI 0.88–1.80, P=0.21). However, the risk of MACE was higher in those reporting binge drinking with less than one episode a month (9.4% vs. 7.7%, HR 1.67, 95% CI 1.32–2.12, P<0.001), as well as in those with at least one episode of binge drinking per month (13.4% vs. 7.7%, HR 2.07, 95% CI 1.62–2.65, P<0.001), when compared to no binge drinking. Conclusion: In contrast to regular heavy alcohol consumption, binge drinking behavior is associated with significant increased risk of MACE 12 months after ACS. Funding Acknowledgement: Type of funding sources: None.
- 28 January 2022
- Published by Elsevier in American Heart Journal
- Vol. 247, 33-41
Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial
- 28 January 2022
- Published by Elsevier in American Heart Journal
- Vol. 247, 33-41
Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial